US FDA approves GSK's twice-yearly asthma drug
The U.S. Food and Drug Administration has approved GSK's add-on drug to treat asthma and a chronic inflammatory sinus condition, the drugmaker said on Tuesday, paving the way for a less frequently...
GSK - GSK plc
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
Stock News
UK approves GSK's twice-yearly asthma drug
UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged 12 and older, as well as for a chronic inflammatory sinus condition in adults.
GSK's Nucala for COPD and Depemokimab for Asthma Get CHMP Nod in EU
GSK gets CHMP backing for Nucala in COPD and depemokimab in asthma, setting up possible Europe approvals in 2026 for IL-5 therapies.
Market Today: Tech Slumps, Broadcom Tanks; EU Eases ICE Ban
Stock News Tech-led selloff caps tough week: US stocks fell as investors rotated out of mega-cap tech after Broadcom (AVGO) and Oracle (ORCL) stoked AI-spending
GSK: Depemokimab And Jemperli Lead Next Wave (Rating Upgrade)
GSK has been impressing me with strong revenue and EPS numbers for the eighth quarter in a row. Also, on December 12, depemokimab, GSK's anti-IL-5 antibody with 6-month dosing, received a positive...
GSK's $4 Billion Asthma Drug Gets First-Ever Green Light in Europe
Analysts are increasingly focusing on GSK (GSK) after Europe's drug regulator delivered what could be a pivotal endorsement for depemokimab, a treatment positio
GSK Expands Use Of Urinary Tract Infection Drug For Gonorrhoea Patients
GSK secures FDA approval for its oral gonorrhoea drug as EMA backs expanded RSV vaccine and additional respiratory treatments.
GSK Gets FDA Nod for Blujepa in Uncomplicated Urogenital Gonorrhea
GSK wins FDA approval for Blujepa, a new oral antibiotic treatment option for uncomplicated urogenital gonorrhea.
GSK gets EU regulator backing for expanded use of RSV vaccine
GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory syncytial virus (RSV) vaccine, Arexvy, for all adults above the age of 18, paving the way for broader use.
European health regulator recommends approval for GSK's twice yearly asthma drug
The European Medicines Agency has recommended the approval of GSK's add-on drug to treat asthma and a chronic inflammatory sinus condition, the company said on Friday.
US FDA approves GSK's oral treatment for gonorrhea
The U.S. Food and Drug Administration on Thursday approved GSK's oral treatment for gonorrhea, a sexually transmitted infection.
GSK's Risvutatug Rezetecan Gets FDA's Orphan Drug Tag in Lung Cancer
GSK gains FDA Orphan Drug Designation for risvutatug rezetecan, adding momentum to its fast-advancing solid-tumor pipeline.
GSK Stock Up Almost 19% in 3 Months: Should You Buy, Hold or Sell?
GSK's stock surge rides on strong Q3 results and raised guidance, as Specialty Medicines momentum offsets U.S. vaccine softness.
Here's Why GSK (GSK) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK drug for aggressive lung cancer wins US orphan status
GSK PLC (LSE:GSK, NYSE:GSK) has picked up another regulatory boost for its experimental cancer medicine risvutatug rezetecan, after the US Food and Drug Administration granted the treatment Orphan...
GSK drug for aggressive lung cancer wins US orphan status
GSK PLC (LSE:GSK, NYSE:GSK) has picked up another regulatory boost for its experimental cancer medicine risvutatug rezetecan, after the US Food and Drug...
Oxford BioTherapeutics Enters into a Strategic Collaboration with GSK to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer
Oxford, UK and San Jose, California , 10th December 2025 – Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and Antibody Drug Conjugate...
Leading bank tips AstraZeneca as 2026's standout UK pharma, with GSK left trailing
JPMorgan has put AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) at the top of its UK healthcare picks for 2026, arguing that the company enters the new year with one of the most catalyst-rich pipelines in...
Why GSK (GSK) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
AnaptysBio shares tumble after legal fight with GSK over cancer drug license
Shares of AnaptysBio fell 14% in premarket trading on Friday after the U.S. drug developer and Tesaro, a unit of Britain's GSK , filed lawsuits against each other, with both claiming a breach in a...
Price Targets
CFRA Upgrades GlaxoSmithKline (GSK) to Buy
$53.00
(was $46.67)
Wan Nurhayati
·
CFRA
GSK initiated with a Neutral at BNP Paribas Exane
$35.25
(was $35.68)
Peter Verdult
·
BNP Paribas
GSK price target raised to $53 from $52.50 at Jefferies
$53.00
(was $38.38)
Peter Welford
·
Jefferies
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields
$36.00
(was $40.69)
Vamil Divan
·
Guggenheim
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields
$85.00
(was $40.69)
Mark Purcell
·
Morgan Stanley